


Amendments to the Claims:

1. (Currently amended) A method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I)



(I)


wherein R¹ is hydrogen and R² is methyl ~~are each independently hydrogen or C1-C4 alkyl;~~ or a pharmaceutically acceptable salt thereof.

2-4. (Cancelled)

5. (Original) A method according to claim 1 wherein said patient is a human diagnosed with prostate cancer.

6. (Cancelled)

7. (Currently amended) A method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I)



(I)


wherein R¹ is hydrogen and R² is methyl ~~are each independently hydrogen or C1-C4 alkyl;~~ or a pharmaceutically acceptable salt thereof.

8-10. (Cancelled)

11. (Original) A method according to claim 7 wherein said patient is a human diagnosed with androgen-independent prostatic adenocarcinoma.

12. (Cancelled)

13. (Withdrawn) A method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I)



wherein R^1 and R^2 are each independently hydrogen or C1-C4 alkyl; or a pharmaceutically acceptable salt thereof.

14. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is glioblastoma.

15. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is colon cancer.

16. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is pancreatic cancer.

17. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is ovarian cancer.


18. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is endometrial cancer.

19. (Withdrawn) A method according to claim 13 wherein said AKT-mediated disease is renal cell cancer.

20. (Withdrawn) A method according to claim 13 wherein R^1 is hydrogen and R^2 is methyl, or a pharmaceutically acceptable salt thereof.

21-36. (Cancelled)

37. (New) A method of inducing prostate cancer cell apoptosis in a patient with prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I)



(I)

wherein R¹ is hydrogen and R² is methyl; or a pharmaceutically acceptable salt thereof.

38. (New) A method according to claim 37 wherein the prostate cancer is androgen-independent prostatic adenocarcinoma.